An ambiguous decision by the Supreme Court has paved the way for frivolous petitions for compensation and clarity is needed, say Daniel Sanchez and Karla Olvera of Olivares.
Securing IP protection in Brazil for the ‘bio-ink’ used to print new human tissue has challenges but composition is key, say Priscila Kashiwabara and Breno Souza of Kasznar Leonardos.
If the right steps are taken, the US International Trade Commission is an attractive option for firms fearing the loss of their valuable IP, say Mary Prendergast, Mark Whitaker and Nicole Ang of Morrison Foerster.
In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith.
Amid criticism against restrictive covenants such as non-competes, what can life sciences firms do to keep their trade secrets safe and defend against unfair competition, ask David Pardue, Patti Bartis, and Sarah Hutchins of Parker Poe.
Certain problems with the patent opposition process need to be addressed in order to protect patent owners, say Alejandro Luna and Luz Elena Elias of Olivares.
It may not be straightforward but it is possible to obtain protection for valuable combination patents in Brazil, say Lívia Figueiredo and Priscila Kashiwabara of Kasznar Leonardos Intellectual Property.
Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.
As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.